Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: Metastasis to the pancreas is rare, and the benefit of resection for secondary pancreatic cancer is poorly defined. Furthermore, there are no guidelines for pancreatic metastasectomy in such patients. The purpose of this study was to discuss our experience with the operative management of secondary pancreatic cancer.
Patients And Methods: This retrospective study included 76 patients who underwent pancreatic metastasectomy for secondary pancreatic cancer between January 2000 and December 2020 at Samsung Medical Center, Seoul, Republic of Korea.
Results: Among the study subjects, 44 underwent distal pancreatectomy, 21 pancreaticoduodenectomy, 5 total pancreatectomy, and 6 enucleation or wedge resection for metastasis. The overall survival (OS) and recurrence-free survival (RFS) were higher in the patients with RCC than in patients with other malignancies (p=0.004 and p=0.051, respectively). Statistically significant differences were not observed in OS and RFS between patients with right RCC (rRCC) or left RCC (lRCC; p=0.523 and p=0.586, respectively).
Conclusion: Pancreatic metastasectomy may offer promising outcomes regarding curative intent in instances of secondary pancreatic metastasis, particularly in the context of RCC. However, regarding the side of primary RCC, no statistically significant differences were found in OS and RFS between rRCC and lRCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.16861 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term survival in a patient with postoperative pulmonary oligometastasis of pancreatic cancer treated with surgical resection and chemotherapy: A case report.
Medicine (Baltimore)
August 2025
Department of Gastroenterology, Hirose Hospital, Imabari, Ehime, Japan.
Rationale: Pancreatic cancer (PC) frequently recurs after curative surgery. Pulmonary metastases are uncommon but may indicate more indolent disease. The benefit of aggressive treatment in cases with minimal dissemination remains unclear.
View Article and Find Full Text PDFSynchronous surgery combined preoperative chemotherapy benefits patients suffering pancreatic ductal adenocarcinoma with liver metastases: a systematic review and meta-analysis.
Sci Rep
August 2025
Department of General Surgery, Division of Pancreatic Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, People's Republic of China.
Recent studies have considered pancreatectomy combined with synchronous metastasectomy as a potential treatment option for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). This study aimed to evaluate the role of surgery in PDAC patients with hepatic metastases and to identify the prognostic factors. PubMed, Embase, and Cochrane Library databases were searched and the hazard ratio (HR) with 95% confidence interval (CI) was extracted from eligible studies.
View Article and Find Full Text PDFSurgical treatment and locoregional therapy of liver metastases from pancreatic ductal adenocarcinoma: review of current strategies.
Minerva Surg
August 2025
Unit of General Surgery, Vito Fazzi Hospital, Lecce, Italy.
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer, with a 5-year survival of 8-10%. Approximately 50% of cases present with metastases at time of diagnosis, with the liver representing the most common site. International guidelines recommend palliative chemotherapy for metastatic disease, yet several studies report prolonged survival after surgery or locoregional therapy in selected patients with both synchronous and metachronous liver metastases (LM).
View Article and Find Full Text PDFRenal cell carcinoma with metastasis to the pancreas: a model for oligometastasis, oligoprogression and metastatic organotropism.
Clin Exp Metastasis
July 2025
Department of Oncology, Stavanger University Hospital, Stavanger, Norway.
Metastatic cancer has been considered uniformly fatal in the past with very poor outcomes for most cancer sites. However, novel systemic and targeted therapies have rendered unique responses with longer survival across several cancer types and metastatic sites. In addition, improved surgical experience and safety with good outcomes has made metastasectomy as an alternative curative-intent treatment across multiple organ sites.
View Article and Find Full Text PDFThe Organ-Specific Prognostic Value of TP53 Mutations in Pancreatic Cancer Patients with Oligometastasis Following Surgical Resection.
Ann Surg
July 2025
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, USA.
Objective: To investigate the prognostic value of KRAS and TP53 in oligometastatic pancreatic ductal adenocarcinoma (PDAC) and compare oncologic outcomes after curative-intent surgery.
Summary Background Data: The current patient selection criteria for surgery on PDAC oligometastasis remain unclear.
Methods: PDAC patients with oligometastasis who underwent surgical resection between 2009 and 2023 were identified.